Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-07-26
1998-02-10
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
426 69, 426648, 426656, 426657, 514 21, 514423, 514529, 514557, 514563, A23L 1305, A61K 3119, A61K 3122, A61K 3801
Patent
active
057169268
ABSTRACT:
The present invention is based in part upon the discovery that the use of pyruvate in enteral formulations, in combination with an anabolic protein composition, produces a synergistic effect in increasing the lean body mass or muscle tissue of a mammal consuming same. The present invention also provides a method for enhanced endurance of athletes. The present invention relates generally to a composition for enhancing the protein concentration or muscle mass of a mammal and a method for enhancing the protein concentration or muscle mass in a mammal. More specifically, the present invention relates to a composition which comprises pyruvate and/or derivatives of pyruvate and an anabolic protein composition. The method of the present invention comprises administering to a mammal in need of enhancing its protein concentration or muscle mass, a composition comprising pyruvate and an anabolic protein composition. The pyruvate/anabolic protein composition can take the form of powders, liquids, pills, capsules, tablets, food additives, candies or confections.
REFERENCES:
patent: 4042688 (1977-08-01), Gans et al.
patent: 4351835 (1982-09-01), Stanko
patent: 4415576 (1983-11-01), Stanko
patent: 4548937 (1985-10-01), Stanko
patent: 4645764 (1987-02-01), Stanko
patent: 4687782 (1987-08-01), Brantman
patent: 4812479 (1989-03-01), Stanko
patent: 4871550 (1989-10-01), Millman
patent: 4874790 (1989-10-01), Stanko
patent: 4981687 (1991-01-01), Fregly et al.
patent: 4988515 (1991-01-01), Buckberg
patent: 5026721 (1991-06-01), Dudrick et al.
patent: 5028440 (1991-07-01), Nissen
patent: 5087472 (1992-02-01), Nissen
patent: 5089477 (1992-02-01), Fregly et al.
patent: 5134162 (1992-07-01), Stanko
patent: 5143842 (1992-09-01), Ham et al.
patent: 5147650 (1992-09-01), Fregly et al.
patent: 5183674 (1993-02-01), Olin
patent: 5236712 (1993-08-01), Fregly et al.
patent: 5238684 (1993-08-01), Fregly et al.
patent: 5256697 (1993-10-01), Miller et al.
patent: 5283260 (1994-02-01), Miller et al.
patent: 5294606 (1994-03-01), Hastings
patent: 5294641 (1994-03-01), Stanko
patent: 5312985 (1994-05-01), Dhaon et al.
patent: 5348979 (1994-09-01), Nissen et al.
patent: 5360613 (1994-11-01), Nissen
patent: 5428072 (1995-06-01), Cook et al.
patent: 5430066 (1995-07-01), Cook et al.
patent: 5472980 (1995-12-01), Miller
patent: 5480909 (1996-01-01), Stanko
patent: 5508308 (1996-04-01), Miller et al.
patent: 5536751 (1996-07-01), Bunger
"Conjugated Linoleic Acid (CLA)", 1996 Supplement Review 19-22 1996.
Monteleone, et al., "Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men", European Journal at Clinical Pharmacology, 1992.
Monteleone, et al., "Effects of Phosphatidylserine on the Neuroendocrine Response to Physical Stress in Humans", Neuroendocrinology, 1990; 52:243-248.
Nestler, et al., "Dehydroepiandrosterone Reduces Serum Low Density Lipoprotein Levels and Body Fat but Does not Alter Insulin Sensitivity in Normal Men", Journal of Clinical Endocrinology and Metabolism, vol. 66, No. 1:57-61, 1988.
Morales, et al., "Effects of Replacement Dose of Dehydroepianodrosterone in Men and Women of Advancing Age", Journal of Clinical Endocrinology and Metabolism, vol. 78, No. 6:1360-1367, 1994.
Kurzman, et al., "Reduction in Body Weight and Cholesterol in Spontaneously Obese Dogs By Dehydroepiandrosterone", International Journal of Obesity, 14:95-104, 1990.
Heymsfield, et al., "Chemical and elemental analysis of humans in vivo using improved body compositon models", American Journal of Physiology, 261:E190-E198, 1991.
Brunner, "HMB, KIC and Leucine--Anticatabolic Bodybuilding Nutrients From the Same Branched Chain", IM, 100-101, Jul. 1996.
Fritz, "Phosphatidylserine--Have We Found a Medically Proven Cortisol Antagonist at Last?", IM, 74-75, Feb. 1996.
Brunner, "Phosphatidylserine", IM, 68-70, Aug. 1996.
Block, "Amino Acid Handbook--Methods and Results of Protein Analysis", (1956).
"MLO--Gain Muscle & Lose Bodyfat--Hardbody--Muscle-Zyme/Questions & Answers", Pamphlet, pp. 1-18 (Not Dated).
"MLO--Hardbody--Muscle-Zyme", Sample Product Label, (Not Dated).
"First Strike--World's First Cortisol Blocker", Sales Aide, (Not Dated).
"Atletika--Thriad Centered Training", Sales Brochure, (1995).
"Cortistat--PS", Advertisement (Not Dated).
"Develop Peak Performance Naturally--Corti-PS Sports Supplement ", Sales Aide, (Not Dated).
"Corti-PS-30P", Technical Data Sheet, (1996).
"Corti-PS-20P", Technical Data Sheet, (1996).
"Corti-PS-20F", Technical Data Sheet, (1996).
Memorandum regarding Corti-PS Phosphatidylserine (PS) dated Aug. 24, 1995.
Beale Paxton K.
Nickey Donald O.
Beale Paxton K.
Nickey Donald O.
Russel Jeffrey E.
LandOfFree
Composition of pyruvate and protein and method for increasing pr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition of pyruvate and protein and method for increasing pr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition of pyruvate and protein and method for increasing pr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2077273